Mammalian target of rapamycin as a target in hematological malignancies

被引：15

作者：

Kelly, Kevin R. ^{[1
]}

Rowe, Julie H. ^{[1
]}

Padmanabhan, Swaminathan ^{[1
]}

Nawrocki, Steffan T. ^{[1
]}

Carew, Jennifer S. ^{[1
]}

机构：

[1] Univ Texas Hlth Sci Ctr San Antonio, Inst Drug Dev, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA

来源：

TARGETED ONCOLOGY | 2011年 / 6卷 / 01期

关键词：

mTOR; Hematological malignancies; Novel agents; Targeted therapy; ACUTE MYELOID-LEUKEMIA; MANTLE CELL LYMPHOMA; SINGLE-AGENT TEMSIROLIMUS; PHASE-II TRIAL; EVERY; WEEKS; MULTIPLE-MYELOMA; IN-VIVO; INHIBITOR EVEROLIMUS; PHOSPHOINOSITIDE; 3-KINASE; DEFOROLIMUS AP23573;

D O I：

10.1007/s11523-011-0175-8

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The mammalian target of rapamycin (mTOR) regulates protein synthesis in addition to cell growth and cell proliferation. Elucidation of the roles of the phosphatidylinositol 3-kinase (PI3K)/Akt/mTOR pathway in the regulation of the pathogenesis of hematological neoplasms has led to the development and clinical evaluation of agents targeting this pathway for the treatment of leukemia and lymphomas. Clinical trials conducted to date have shown modest responses to mTOR inhibition in patients with various hematological malignancies. Novel agents that simultaneously target mTOR complex 2 (mTORC2) or AKT in addition to mTOR complex 1 (mTORC1) may offer an opportunity to improve therapeutic efficacy.

引用

页码：53 / 61

页数：9

共 50 条

[1] Mammalian target of rapamycin as a target in hematological malignancies
Kevin R. Kelly
Julie H. Rowe
Swaminathan Padmanabhan
Steffan T. Nawrocki
Jennifer S. Carew
Targeted Oncology, 2011, 6
[2] Emerging roles for mammalian target of rapamycin inhibitors in the treatment of solid tumors and hematological malignancies
Khokhar, Nushmia Z.
Altman, Jessica K.
Platanias, Leonidas C.
CURRENT OPINION IN ONCOLOGY, 2011, 23 (06) : 578 - 586
[3] Clinical activity of mammalian target of rapamycin inhibitors in solid tumors
Alvarado, Yesid
Mita, Monica M.
Vemulapalli, Sushma
Mahalingam, Devalingam
Mita, Alain C.
TARGETED ONCOLOGY, 2011, 6 (02) : 69 - 94
[4] The mammalian target of rapamycin pathway as a therapeutic target in multiple myeloma
Gera, Joseph
Lichtenstein, Alan
LEUKEMIA & LYMPHOMA, 2011, 52 (10) : 1857 - 1866
[5] The Immunoproteasome as a Therapeutic Target for Hematological Malignancies
Miller, Zachary
Lee, Wooin
Kim, Kyung Bo
CURRENT CANCER DRUG TARGETS, 2014, 14 (06) : 537 - 548
[6] Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies
Coiffier, Bertrand
Ribrag, Vincent
LEUKEMIA & LYMPHOMA, 2009, 50 (12) : 1916 - 1930
[7] Mammalian target of rapamycin as a therapeutic target in leukemia
Giles, FJ
Albitar, M
CURRENT MOLECULAR MEDICINE, 2005, 5 (07) : 653 - 661
[8] Mammalian target of rapamycin as a therapeutic target in oncology
Abraham, Robert T.
Eng, Christina H.
EXPERT OPINION ON THERAPEUTIC TARGETS, 2008, 12 (02) : 209 - 222
[9] Promising Activity of Mammalian Target of Rapamycin Inhibitors in Hematologic Malignancies Therapy
Fuchs, Ota
CURRENT SIGNAL TRANSDUCTION THERAPY, 2011, 6 (01) : 44 - 54
[10] Mammalian target of rapamycin (mTOR)
Yonezawa, K
NASH AND NUTRITIONAL THERAPY, 2005, : 92 - 99

← 1 2 3 4 5 →